Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today ...
The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...
Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...
Funding for HIV care and prevention are key for continued progress, but recent cuts to federal funding for health agencies, ...
New diagnoses of HIV and syphilis have doubled in Florida since 2020. St. Lucie County has the highest rate of new HIV cases ...
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
12don MSN
Early HIV drugs give immune system a brief reprieve before dysregulation returns, study finds
Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term.
Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...
Zacks Investment Research on MSN
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
Gilead Sciences, Inc. GILD announced that its investigational single-tablet regimen (STR) of bictegravir and lenacapavir for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback